$IPA IPA’s Subsidiary BioStrand Unveils Use Case
Post# of 98049
(Total Views: 109)
Posted On: 06/13/2023 1:34:57 PM
$IPA IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
https://www.businesswire.com/news/home/20230613363256/en/
VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma (IID) solution developed by its subsidiary, BioStrand®.
Link to use case here
The IID has long been a significant challenge in the biotechnology industry, with researchers and investors grappling with the complexities of integrating diverse data types to gain meaningful insights. BioStrand's LENSaiTM platform and patented HYFT® technology have successfully addressed this issue, providing a unified framework that encapsulates and integrates diverse data modalities, including syntactical (sequence) data, 3D structural data, unstructured scientific information, and more.
This breakthrough approach has paved the way for quicker and more potent biological discoveries, and the unveiling of this use case demonstrates the practical application of this technology in the field of biotechnology. This use case provides a detailed look at how HYFT technology and the LENSai platform can be utilized to solve complex biological problems, offering a glimpse into the future of biotherapeutic research and development.
"Our newest use case stands as a potent testament to how we've successfully navigated the IID. It demonstrates the power of integrating and organizing heterogeneous data types and reflects depth of insights gleamed using our comprehensive knowledge graph. This graph, teeming with over 25 billion relations, bridges the gap between sequence, structure, and textual data in a manner that was previously inconceivable. The application of these interconnections has unearthed insights and relationships that were otherwise invisible, enhancing our understanding of biological systems,” said Dr. Jennifer Bath, President and CEO.
The unveiling of this use case is a testament to ImmunoPrecise's commitment to innovation and its dedication to solving complex problems in the field of biotechnology. The company continues to lead the way in AI-driven biotherapeutic research and technology, and this latest development further solidifies its position as a pioneer in the industry.
https://www.businesswire.com/news/home/20230613363256/en/
VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma (IID) solution developed by its subsidiary, BioStrand®.
Link to use case here
The IID has long been a significant challenge in the biotechnology industry, with researchers and investors grappling with the complexities of integrating diverse data types to gain meaningful insights. BioStrand's LENSaiTM platform and patented HYFT® technology have successfully addressed this issue, providing a unified framework that encapsulates and integrates diverse data modalities, including syntactical (sequence) data, 3D structural data, unstructured scientific information, and more.
This breakthrough approach has paved the way for quicker and more potent biological discoveries, and the unveiling of this use case demonstrates the practical application of this technology in the field of biotechnology. This use case provides a detailed look at how HYFT technology and the LENSai platform can be utilized to solve complex biological problems, offering a glimpse into the future of biotherapeutic research and development.
"Our newest use case stands as a potent testament to how we've successfully navigated the IID. It demonstrates the power of integrating and organizing heterogeneous data types and reflects depth of insights gleamed using our comprehensive knowledge graph. This graph, teeming with over 25 billion relations, bridges the gap between sequence, structure, and textual data in a manner that was previously inconceivable. The application of these interconnections has unearthed insights and relationships that were otherwise invisible, enhancing our understanding of biological systems,” said Dr. Jennifer Bath, President and CEO.
The unveiling of this use case is a testament to ImmunoPrecise's commitment to innovation and its dedication to solving complex problems in the field of biotechnology. The company continues to lead the way in AI-driven biotherapeutic research and technology, and this latest development further solidifies its position as a pioneer in the industry.
(0)
(0)Scroll down for more posts ▼